Wilson I Gonsalves
Mayo Clinic in Rochester · Mayo Clinic Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Wilson I Gonsalves as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:02 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07057583 · A Study of Carbon 13-based Deep Labelling of Bone Marrow CellsMayo Clinic · enrolling by invitation · Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-IgM Monoclonal Gammopathy of Undetermined Significance · principal investigator
- Ph2NCT05288062 · Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaMayo Clinic · terminated · Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph1NCT03829020 · Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaMayo Clinic · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1NCT03798678 · CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaNational Cancer Institute (NCI) · active not recruiting · Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- N/ANCT03119883 · Dysregulation of Glutamine Activity in the Pathogenesis of Multiple MyelomaMayo Clinic · completed · Monoclonal Gammopathy of Undetermined Significance, Plasma Cell Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Assessment of Metabolites Among Asymptomatic Precursor and Malignant Monoclonal GammopathiesR01CA254961 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2021 to 2024 · $345,528 awarded in 2024Same name and institution; not confirmed by an ID
- Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple MyelomaK23CA218742 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2017 to 2019 · $170,856 awarded in 2019Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 EmphasisUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2014 to 2019Named on NCT03798678
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:02 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Quantification of clonal circulating plasma cells in relapsed multiple myeloma.Br J Haematol · 201473 citationsRCR 2.1
- Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.Am J Hematol · 202058 citationsRCR 2.4
- 57 citationsRCR 1.9
- Second auto-SCT for treatment of relapsed multiple myeloma.Bone Marrow Transplant · 201356 citationsRCR 1.6
- Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.Am J Hematol · 201943 citationsRCR 2.1
- Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.Blood Adv · 202028 citationsRCR 1.2
- Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.Biol Blood Marrow Transplant · 201821 citationsRCR 0.6
- Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.Am J Hematol · 201916 citationsRCR 0.7
- Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.Leukemia · 201814 citationsRCR 0.4
- Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.Am J Hematol · 201914 citationsRCR 0.5